CA2413033A1 - Agent de contraste fluorescent dans le proche infrarouge et imagerie par fluorescence - Google Patents

Agent de contraste fluorescent dans le proche infrarouge et imagerie par fluorescence Download PDF

Info

Publication number: CA2413033A1
Authority: CA; Canada
Prior art keywords: compound; s03na; na03s; salt; formula
Prior art date: 1998-09-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002413033A

Other languages

English (en)

Inventor

Naoto Miwa

Hiroaki Eguchi

Yoshio Inagaki

Michihito Inagaki

Masafumi Okumura

Toru Harada

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Fujifilm Holdings Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-18

Filing date

1999-09-16

Publication date

2000-03-30

1998-09-18 Priority claimed from JP10283301A external-priority patent/JP2000095758A/ja

1999-09-16 Application filed by Individual filed Critical Individual

2000-03-30 Publication of CA2413033A1 publication Critical patent/CA2413033A1/fr

Status Abandoned legal-status Critical Current

Links

239000002872 contrast media Substances 0.000 title claims abstract description 60
238000000799 fluorescence microscopy Methods 0.000 title description 14
159000000000 sodium salts Chemical class 0.000 claims abstract description 37
206010028980 Neoplasm Diseases 0.000 claims description 18
238000003384 imaging method Methods 0.000 claims description 13
238000002583 angiography Methods 0.000 claims description 4
150000001875 compounds Chemical class 0.000 abstract description 260
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 105
-1 porphyrin compound Chemical class 0.000 description 81
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 57
229910001868 water Inorganic materials 0.000 description 55
150000003839 salts Chemical class 0.000 description 52
125000000542 sulfonic acid group Chemical group 0.000 description 46
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
125000000217 alkyl group Chemical group 0.000 description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
239000013078 crystal Substances 0.000 description 34
239000000203 mixture Substances 0.000 description 28
238000000034 method Methods 0.000 description 23
238000001914 filtration Methods 0.000 description 22
239000011734 sodium Substances 0.000 description 22
MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 18
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 18
239000001632 sodium acetate Substances 0.000 description 18
235000017281 sodium acetate Nutrition 0.000 description 18
125000004432 carbon atom Chemical group C* 0.000 description 16
230000005284 excitation Effects 0.000 description 16
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 16
125000001424 substituent group Chemical group 0.000 description 16
239000000243 solution Substances 0.000 description 15
241000699670 Mus sp. Species 0.000 description 14
238000002835 absorbance Methods 0.000 description 14
238000010521 absorption reaction Methods 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
238000007706 flame test Methods 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
238000012360 testing method Methods 0.000 description 13
229940086542 triethylamine Drugs 0.000 description 13
210000001519 tissue Anatomy 0.000 description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
239000000706 filtrate Substances 0.000 description 10
125000000623 heterocyclic group Chemical group 0.000 description 10
210000004204 blood vessel Anatomy 0.000 description 9
125000005842 heteroatom Chemical group 0.000 description 9
229910052708 sodium Inorganic materials 0.000 description 9
239000002904 solvent Substances 0.000 description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
238000000862 absorption spectrum Methods 0.000 description 8
150000002500 ions Chemical class 0.000 description 8
ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 8
239000002253 acid Substances 0.000 description 7
125000003277 amino group Chemical group 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
239000002585 base Substances 0.000 description 7
125000005843 halogen group Chemical group 0.000 description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
238000010189 synthetic method Methods 0.000 description 7
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
125000003545 alkoxy group Chemical group 0.000 description 6
230000037396 body weight Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000002073 fluorescence micrograph Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
125000005605 benzo group Chemical group 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
239000000975 dye Substances 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
239000011591 potassium Substances 0.000 description 5
229910052700 potassium Inorganic materials 0.000 description 5
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
125000004964 sulfoalkyl group Chemical group 0.000 description 5
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
150000003863 ammonium salts Chemical class 0.000 description 4
125000003710 aryl alkyl group Chemical group 0.000 description 4
230000005540 biological transmission Effects 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 3
101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 3
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
230000007059 acute toxicity Effects 0.000 description 3
231100000403 acute toxicity Toxicity 0.000 description 3
239000000654 additive Substances 0.000 description 3
125000005110 aryl thio group Chemical group 0.000 description 3
239000011575 calcium Substances 0.000 description 3
159000000007 calcium salts Chemical class 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
230000003902 lesion Effects 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
238000005192 partition Methods 0.000 description 3
238000002428 photodynamic therapy Methods 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
DRORSPJLYCDESA-UHFFFAOYSA-N 4,4-dimethylcyclohexene Chemical group CC1(C)CCC=CC1 DRORSPJLYCDESA-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000004163 cytometry Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
150000007524 organic acids Chemical group 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical class C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical class CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical group OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101100278987 Arabidopsis thaliana ECH2 gene Proteins 0.000 description 1
101150026868 CHS1 gene Proteins 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102100025597 Caspase-4 Human genes 0.000 description 1
241000725101 Clea Species 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
101100273284 Homo sapiens CASP4 gene Proteins 0.000 description 1
101000913968 Ipomoea purpurea Chalcone synthase C Proteins 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
101000907988 Petunia hybrida Chalcone-flavanone isomerase C Proteins 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
239000012891 Ringer solution Substances 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
235000010724 Wisteria floribunda Nutrition 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000005352 clarification Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
229960004657 indocyanine green Drugs 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
MHYFEEDKONKGEB-UHFFFAOYSA-N oxathiane 2,2-dioxide Chemical compound O=S1(=O)CCCCO1 MHYFEEDKONKGEB-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
208000007578 phototoxic dermatitis Diseases 0.000 description 1
231100000018 phototoxicity Toxicity 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
229960002078 sevoflurane Drugs 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
125000004436 sodium atom Chemical group 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
238000012285 ultrasound imaging Methods 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002413033A 1998-09-18 1999-09-16 Agent de contraste fluorescent dans le proche infrarouge et imagerie par fluorescence Abandoned CA2413033A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP10283301A JP2000095758A (ja)	1998-09-18	1998-09-18	近赤外蛍光造影剤および蛍光造影方法
JP10/283301		1998-09-18
CA002344315A CA2344315A1 (fr)	1998-09-18	1999-09-16	Agent de contraste fluorescent dans le proche infrarouge et imagerie par fluorescence

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002344315A Division CA2344315A1 (fr)	1998-09-18	1999-09-16	Agent de contraste fluorescent dans le proche infrarouge et imagerie par fluorescence

Publications (1)

Publication Number	Publication Date
CA2413033A1 true CA2413033A1 (fr)	2000-03-30

Family

ID=25682516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002413033A Abandoned CA2413033A1 (fr)	1998-09-18	1999-09-16	Agent de contraste fluorescent dans le proche infrarouge et imagerie par fluorescence

Country Status (1)

Country	Link
CA (1)	CA2413033A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6915154B1 (en)	1999-09-24	2005-07-05	National Research Council Of Canada	Method and apparatus for performing intra-operative angiography
US7881777B2 (en)	1999-09-24	2011-02-01	National Research Council Of Canada	Method and apparatus for performing intra-operative angiography
CN103038289A (zh) *	2010-05-31	2013-04-10	阿拉美迪克斯两合公司	作为造影剂的萘并花菁
US9421280B2 (en)	2005-04-26	2016-08-23	Novadaq Technologies Inc.	Real time imaging during solid organ transplant
US9610021B2 (en)	2008-01-25	2017-04-04	Novadaq Technologies Inc.	Method for evaluating blush in myocardial tissue
US9816930B2 (en)	2014-09-29	2017-11-14	Novadaq Technologies Inc.	Imaging a target fluorophore in a biological material in the presence of autofluorescence
US10041042B2 (en)	2008-05-02	2018-08-07	Novadaq Technologies ULC	Methods for production and use of substance-loaded erythrocytes (S-IEs) for observation and treatment of microvascular hemodynamics
US10219742B2 (en)	2008-04-14	2019-03-05	Novadaq Technologies ULC	Locating and analyzing perforator flaps for plastic and reconstructive surgery
US10265419B2 (en)	2005-09-02	2019-04-23	Novadaq Technologies ULC	Intraoperative determination of nerve location
US10278585B2 (en)	2012-06-21	2019-05-07	Novadaq Technologies ULC	Quantification and analysis of angiography and perfusion
US10434190B2 (en)	2006-09-07	2019-10-08	Novadaq Technologies ULC	Pre-and-intra-operative localization of penile sentinel nodes
US10492671B2 (en)	2009-05-08	2019-12-03	Novadaq Technologies ULC	Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US10631746B2 (en)	2014-10-09	2020-04-28	Novadaq Technologies ULC	Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
US10992848B2 (en)	2017-02-10	2021-04-27	Novadaq Technologies ULC	Open-field handheld fluorescence imaging systems and methods

1999
- 1999-09-16 CA CA002413033A patent/CA2413033A1/fr not_active Abandoned

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7881777B2 (en)	1999-09-24	2011-02-01	National Research Council Of Canada	Method and apparatus for performing intra-operative angiography
US8892190B2 (en)	1999-09-24	2014-11-18	National Research Council Of Canada	Method and apparatus for performing intra-operative angiography
US6915154B1 (en)	1999-09-24	2005-07-05	National Research Council Of Canada	Method and apparatus for performing intra-operative angiography
US9421280B2 (en)	2005-04-26	2016-08-23	Novadaq Technologies Inc.	Real time imaging during solid organ transplant
US10265419B2 (en)	2005-09-02	2019-04-23	Novadaq Technologies ULC	Intraoperative determination of nerve location
US10434190B2 (en)	2006-09-07	2019-10-08	Novadaq Technologies ULC	Pre-and-intra-operative localization of penile sentinel nodes
US9610021B2 (en)	2008-01-25	2017-04-04	Novadaq Technologies Inc.	Method for evaluating blush in myocardial tissue
US11564583B2 (en)	2008-01-25	2023-01-31	Stryker European Operations Limited	Method for evaluating blush in myocardial tissue
US9936887B2 (en)	2008-01-25	2018-04-10	Novadaq Technologies ULC	Method for evaluating blush in myocardial tissue
US10835138B2 (en)	2008-01-25	2020-11-17	Stryker European Operations Limited	Method for evaluating blush in myocardial tissue
US10219742B2 (en)	2008-04-14	2019-03-05	Novadaq Technologies ULC	Locating and analyzing perforator flaps for plastic and reconstructive surgery
US10041042B2 (en)	2008-05-02	2018-08-07	Novadaq Technologies ULC	Methods for production and use of substance-loaded erythrocytes (S-IEs) for observation and treatment of microvascular hemodynamics
US10492671B2 (en)	2009-05-08	2019-12-03	Novadaq Technologies ULC	Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
CN103038289B (zh) *	2010-05-31	2015-07-29	阿拉美迪克斯两合公司	作为造影剂的萘并花菁
CN103038289A (zh) *	2010-05-31	2013-04-10	阿拉美迪克斯两合公司	作为造影剂的萘并花菁
US10278585B2 (en)	2012-06-21	2019-05-07	Novadaq Technologies ULC	Quantification and analysis of angiography and perfusion
US11284801B2 (en)	2012-06-21	2022-03-29	Stryker European Operations Limited	Quantification and analysis of angiography and perfusion
US12186055B2 (en)	2012-06-21	2025-01-07	Stryker Corporation	Quantification and analysis of angiography and perfusion
US10488340B2 (en)	2014-09-29	2019-11-26	Novadaq Technologies ULC	Imaging a target fluorophore in a biological material in the presence of autofluorescence
US9816930B2 (en)	2014-09-29	2017-11-14	Novadaq Technologies Inc.	Imaging a target fluorophore in a biological material in the presence of autofluorescence
US10631746B2 (en)	2014-10-09	2020-04-28	Novadaq Technologies ULC	Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
US10992848B2 (en)	2017-02-10	2021-04-27	Novadaq Technologies ULC	Open-field handheld fluorescence imaging systems and methods
US11140305B2 (en)	2017-02-10	2021-10-05	Stryker European Operations Limited	Open-field handheld fluorescence imaging systems and methods
US12028600B2 (en)	2017-02-10	2024-07-02	Stryker Corporation	Open-field handheld fluorescence imaging systems and methods
US12464215B2 (en)	2017-02-10	2025-11-04	Stryker Corporation	Open-field handheld fluorescence imaging systems and methods

Publication	Publication Date	Title
AU763991B2 (en)	2003-08-07	Near infrared fluorescent contrast agent and fluorescence imaging
CA2394539C (fr)	2009-10-27	Agent de contraste fluorescent proche infrarouge et imagerie par fluorescence
RU2350355C2 (ru)	2009-03-27	Флюоресцентный контрастирующий агент ближней инфракрасной области спектра и способ флуоресцентной томографии
US7547721B1 (en)	2009-06-16	Near infrared fluorescent contrast agent and fluorescence imaging
CA2413033A1 (fr)	2000-03-30	Agent de contraste fluorescent dans le proche infrarouge et imagerie par fluorescence
US20030180221A1 (en)	2003-09-25	Near infrared fluorescent contrast agent and fluorescence imaging
JP3507060B2 (ja)	2004-03-15	近赤外蛍光造影剤及び蛍光イメージング
NZ525453A (en)	2003-09-26	Near infrared fluorescent contrast agent useful for fluorescence imaging of tumour or in angiography
CZ20022092A3 (cs)	2002-11-13	Fluorescenční kontrastní činidlo vyzařující záření v blízké infračervené oblasti a použití tohoto činidla při fluorescenčním zobrazování
CZ2001987A3 (cs)	2001-07-11	Fluorescenční kontrastní činidlo vyzařující záření v blízké infračervené oblasti a použití tohoto činidla při fluorescenčním zobrazování

Legal Events

Date	Code	Title	Description
2004-09-07	EEER	Examination request
2009-11-23	FZDE	Dead